We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Muhammad Abdul-Ghani

Muhammad Abdul-Ghani MD, PhD

Professor of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas

Muhammad Abdul-Ghani, MD, PhD, is Professor of Medicine in the Diabetes Division at UT Health San Antonio.  His major interests focus on the pathophysiology and treatment of type 2 diabetes and prediabetes.  He has played a pivotal role in defining the mechanism of action of SGLT2 inhibitors and GLP-1 receptor agonists and their combined effect on muscle/hepatic insulin sensitivity and beta cell function.  His research has delineated the distinct pathophysiologic disturbances present in individuals with IGT and IFG and the superiority of the one hour plasma glucose concentration in identifying individuals at risk for future development of diabetes.  He also has been a pioneer in advocating combination therapy with agents that correct specific pathophysiologic defects present in the prediabetic/diabetic state and this work has been funded by the NIDDK/NIH.

Disclosures

Dr. Abdul-Ghani has no relevant disclosures.